Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Buy” by Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given a consensus rating of “Buy” by the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $45.14.

Several equities analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Thursday, September 26th. Oppenheimer assumed coverage on Dianthus Therapeutics in a report on Thursday, October 3rd. They set an “outperform” rating and a $48.00 price target for the company. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Wedbush reduced their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Finally, Robert W. Baird assumed coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 price target for the company.

Dianthus Therapeutics Trading Up 2.3 %

Shares of Dianthus Therapeutics stock opened at $29.41 on Thursday. The firm has a market capitalization of $863.77 million, a P/E ratio of -5.31 and a beta of 1.84. The business has a fifty day simple moving average of $27.72 and a two-hundred day simple moving average of $26.43. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The firm had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Analysts predict that Dianthus Therapeutics will post -2.28 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently bought and sold shares of the business. Bain Capital Life Sciences Investors LLC bought a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at about $89,761,000. RA Capital Management L.P. bought a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at about $69,990,000. Vanguard Group Inc. grew its stake in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after purchasing an additional 384,182 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at about $11,251,000. Finally, Great Point Partners LLC grew its stake in shares of Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after purchasing an additional 132,929 shares during the period. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.